Questions and Answers About KISQALI
Click below for answers to some of the most frequently asked questions about KISQALI® (ribociclib) tablets.
KISQALI® (ribociclib) is a prescription medicine used in combination with:
- an aromatase inhibitor to treat pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic), as the first endocrine-based therapy; or
- fulvestrant to treat postmenopausal women with HR-positive, HER2-negative metastatic breast cancer as the first endocrine-based therapy or with disease progression following endocrine therapy
KISQALI is a targeted treatment for HR+ (ER+ and/or PR+), HER2- metastatic breast cancer that blocks, or interferes with, substances that play a key role in cancer cell growth and survival. KISQALI affects cancer cells, but can also affect healthy cells.
Combination therapy is a treatment strategy of taking multiple medicines. By combining KISQALI and either a nonsteroidal aromatase inhibitor (NSAI) or fulvestrant, you’ll have 2 medicines working differently, but together, to help slow the growth and spread of your metastatic breast cancer.
Click here to see the proven results of KISQALI + hormone therapy or fulvestrant.
Overall survival is about living longer with metastatic breast cancer. Click here to learn how overall survival is different from progression-free survival.
The most common side effects of KISQALI are neutropenia, nausea, infections, fatigue, diarrhea, leukopenia, vomiting, hair loss, headache, constipation, rash, and cough. KISQALI can also cause more serious side effects. Learn more about the potential side effects of KISQALI here.
Although not all side effects can be managed, your health care team may offer suggestions to help manage some of the side effects of KISQALI. It’s important to talk with your doctor or nurse about side effects you experience and the best ways to manage them. Get tips about managing some common side effects here.
KISQALI is a prescription medicine that is a convenient once-daily oral tablet that comes in an easy-to-use blister pack. Your health care provider will prescribe the dose of KISQALI that's right for you. You should take KISQALI exactly as your health care provider tells you. Take KISQALI each day at about the same time, preferably in the morning. Do not change your dose or stop taking KISQALI unless your health care provider tells you. You may take KISQALI with or without food. Ask your doctor about the recommended dose of your nonsteroidal aromatase inhibitor (NSAI) or fulvestrant. Learn more about taking KISQALI here.
Avoid eating grapefruit and avoid drinking grapefruit juice. Also avoid taking St. John's wort (Hypericum perforatum) while taking KISQALI.
The KISQALI® (ribociclib) FEMARA® (letrozole) Co-Pack is a prescription medicine used as the first hormonal based therapy to treat premenopausal, perimenopausal, or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).
The KISQALI FEMARA Co-Pack contains 2 different types of medicines:
- The violet tablet contains the medicine KISQALI (ribociclib).
- The yellow tablet contains the medicine FEMARA (letrozole).
Novartis Pharmaceuticals Corporation is committed to helping make treatment with KISQALI as affordable as possible. Learn about financial resources here.
KISQALI Care is a patient support program that provides those who have been prescribed KISQALI with helpful materials that can be referenced throughout treatment, along with a dedicated navigator who can provide one-on-one assistance. Sign up here.
Yes. The KISQALI Care Patient Support program is completely free to those who have been prescribed KISQALI.
If you take too much KISQALI, call your doctor right away or go to the nearest hospital emergency room. If you miss a dose of KISQALI or vomit after taking a dose of KISQALI, do not take another dose on that day. Take your next dose at your regular time.